AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

VNDA · NASDAQ · Biotechnology

Vanda Pharmaceuticals (VNDA)

Develops and commercializes specialty therapies across psychiatric, sleep, MS, and motion-sickness markets.

$5.15

After hours−0.06 (−1.15%)

At close$5.21(+1.07%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	39	45	47	50	48	53	50	53	56	57	52	51
Cost of revenue	3	3	5	4	3	3	4	4	3	4	5	4
Gross profit	36	42	42	46	45	51	47	48	53	53	47	47
	42	49	51	56	56	61	91	87	85	94	97	111
Research & development	17	24	21	17	17	20	36	22	23	29	28	37
	25	24	30	39	38	39	50	65	60	63	68	72
Selling & marketing	0	1	0	0	0	2	0	0	0	0	0	0
General & administrative	0	23	0	0	0	37	0	0	0	0	0	72
Other expenses	0	1	0	0	2	2	5	0	2	2	0	2
Operating income	−6	−7	−9	−10	−11	−10	−45	−39	−31	−40	−50	−64
	6	5	5	5	5	4	7	4	3	2	2	1
Interest income	6	0	0	0	0	0	0	0	0	0	0	0
Other non-operating income	0	−5	−5	−5	−5	−4	−12	−4	−3	−2	−2	1
Income before tax	0	−2	−5	−6	−6	−6	−37	−35	−28	−38	−48	−62
Income tax expense	0	1	−1	−1	−1	−2	−8	−8	−6	103	0	0
Net income from continuing operations	0	−2	−4	−5	−5	−5	−29	−27	−23	−141	−49	−63
Net income	0	−2	−4	−5	−5	−5	−29	−27	−23	−141	−49	−63
EPS, basic	$0.00	−$0.04	−$0.07	−$0.08	−$0.09	−$0.08	−$0.50	−$0.46	−$0.38	−$2.39	−$0.82	−$1.04
EPS, diluted	$0.00	−$0.04	−$0.07	−$0.08	−$0.09	−$0.08	−$0.50	−$0.46	−$0.38	−$2.39	−$0.82	−$1.04
Weighted average shares, basic	58	58	58	58	58	58	59	59	59	59	59	60
Weighted average shares, diluted	58	58	58	58	58	58	59	59	59	59	59	60
EBITDA	−5	−1	−2	−4	−4	−5	−31	−33	−26	−32	−45	−63
Depreciation & amortization	1	1	2	2	2	2	1	2	2	6	4	2
EBIT	−6	−2	−5	−6	−6	−6	−32	−35	−28	−38	−48	−65